8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Mar 4, 2026·SEC
Viemed Healthcare, Inc.(VMD)Earnings, Financials & Key Ratios
VMD•NASDAQ
$11.69
31.6× P/E·Price updated Jun 25, 2026
AboutViemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment (DME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company also leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), percussion vests, oxygen concentrator units, and other small respiratory equipment; and sells and rents DME and patient medical services. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management related solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.Show more
- Revenue$270M+20.5%
- EBITDA$49M+14.0%
- Net Income$15M+32.6%
- EPS (Diluted)0.37+32.1%
- Gross Margin57.52%-3.2%
- EBITDA Margin18.25%-5.4%
- Operating Margin7.66%-4.0%
- Net Margin5.53%+10.0%
- ROE10.79%+18.4%
VMD Price & Volume
Viemed Healthcare, Inc. (VMD) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Revenue Growth Amidst Structural Margin Compression
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Accelerating
Profitability:Moderate
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Regulatory reimbursement and audit exposure
Key Thesis Takeaways
- Viemed Healthcare demonstrates a robust top-line trajectory with 27.5% year-over-year revenue growth in 2026Q1, driven by successful scaling of its high-acuity respiratory services.
- However, investors should monitor the persistent contraction in gross margins from 63.3% in 2023Q4 to 56.8% in 2026Q1, which suggests potential headwinds from clinical labor costs or unfavorable payer mix shifts.
- While the company maintains a conservative capital structure with a 0.09 debt-to-equity ratio, the volatility in free cash flow and rising stock-based compensation of $2.5 million per quarter warrant a cautious approach to valuation.
Verdict Logic
while the company exhibits strong top-line momentum with 27.5% revenue growth, the compression of gross margins to 56.8% and the reliance on non-cash depreciation to drive an OCF/NI ratio of 3.13 in 2026Q1 suggest limited near-term earnings quality.
VMD Growth Metrics
Viemed Healthcare, Inc. (VMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years22.82%
5 Years15.53%
3 Years24.87%
TTM23.1%
Profit CAGR
10 Years5.28%
5 Years-13.88%
3 Years33.89%
TTM21.19%
EPS CAGR
10 Years-13%
5 Years-14.71%
3 Years35.11%
TTM25.92%
Return on Capital
10 Years21.84%
5 Years12.07%
3 Years13.27%
Last Year13.21%
VMD Recent Earnings
Viemed Healthcare, Inc. (VMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.06-33.3%
$0.09
Rev
$75M+1.4%
$74M
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.14+16.7%
$0.12
Rev
$76M-2.0%
$78M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.09+0.0%
$0.09
Rev
$72M-7.4%
$78M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.08-5.9%
$0.09
Rev
$63M-0.7%
$64M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.06vs $0.09-33.3% | $75Mvs $74M+1.4% |
| Q2 2026 | Mar 4, 2026 | $0.14vs $0.12+16.7% | $76Mvs $78M-2.0% |
| Q4 2025 | Nov 5, 2025 | $0.09vs $0.09+0.0% | $72Mvs $78M-7.4% |
| Q3 2025 | Aug 6, 2025 | $0.08vs $0.09-5.9% | $63Mvs $64M-0.7% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Viemed Healthcare, Inc. (VMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.69 | $448.16M | 31.59 | 20.52% | 5.53% | 10.79% | — | |
| $48.99 | $1.55B | 75.37 | 17.76% | 4.11% | 11.72% | — | |
| $14.71 | $276.88M | -22.29 | 1.46% | -12.52% | -6.77% | — | |
| $13.80 | $706.91M | -152.32 | 2.44% | -0.3% | -0.55% | — | |
| $23.63 | $1.62B | 29.17 | 7.08% | 3.67% | 13.6% | — | |
| $96.86 | $1.81B | 18.59 | 23.21% | 6.89% | 9.34% | — |
Compare VMD vs Peers
Viemed Healthcare, Inc. (VMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VMD SEC Filings & Documents
Viemed Healthcare, Inc. (VMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when VMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VMD Frequently Asked Questions
Viemed Healthcare, Inc. (VMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Viemed Healthcare, Inc.'s revenue?
Viemed Healthcare, Inc. (VMD) reported $286.6M in revenue for fiscal year 2025. This represents a 1130% increase from $23.3M in 2014.
How fast is Viemed Healthcare, Inc. growing?
Viemed Healthcare, Inc. (VMD) grew revenue by 20.5% over the past year. This is strong growth.
Is VMD profitable?
Yes, Viemed Healthcare, Inc. (VMD) is profitable, generating $14.9M in net income for fiscal year 2025 (5.5% net margin).
Dividend & Returns
What is VMD's return on equity?
Viemed Healthcare, Inc. (VMD) has a return on equity (ROE) of 10.8%. This is reasonable for most industries.
What is Viemed Healthcare, Inc.'s free cash flow?
Viemed Healthcare, Inc. (VMD) generated $25.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.